Global strategies are required to cure and eliminate HBV infection.
about
Recent advances in understanding and diagnosing hepatitis B virus infectionSustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs.Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir.Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication.Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.Transforming growth factor β-activated kinase 1 transcriptionally suppresses hepatitis B virus replication.High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status.Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.Disparities in liver cancer occurrence in the United States by race/ethnicity and state.A new class of ribozyme from hepatitis B virus.Activating the innate immune response to counter chronic hepatitis B virus infection.Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.New antivirals for the treatment of chronic hepatitis B.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Alteration of microRNA profiles by a novel inhibitor of human La protein in HBV-transformed human hepatoma cells.A research agenda for curing chronic hepatitis B virus infection.Interference of Apoptosis by Hepatitis B Virus.Untypable genotype restriction patterns and surface gene variants of hepatitis B virus isolates.An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.[A new restriction factor against HBV infection: the SMC5/6 complex].Hepatitis B virus: is a cure possible?Immune checkpoint blockade in infectious diseases.Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation.Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo.LncRNA expression profiles in HBV-transformed human hepatocellular carcinoma cells treated with a novel inhibitor of human La protein.Hepatitis B Virus Infection and Organ Transplantation.Drugs in Development for Hepatitis B.Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells
P2860
Q28067419-5361D670-C16D-44C9-AF4E-676F00CE11ECQ33635361-79034CBF-91D6-4294-8E86-8C2639298EB0Q37287773-DB30EB4B-D24B-4211-B537-30E480BDA293Q37364333-377A7023-6834-40E0-8950-66C433AD3A63Q37540212-2AF34810-175E-4696-AF1A-8B90096D43CBQ37550327-48E86F72-85A6-4745-9850-A37F50C039B9Q38632589-85DBE739-21BC-4175-8205-0F6CD1E94EB0Q38665181-6BC213E3-73FC-43B2-84DE-941DD8702BD1Q38741005-59DA9721-2552-4D15-884A-327CBC06C508Q38834379-B170C13D-B5D4-4A7D-8F8C-8036F10F0CEDQ38948529-C03DD67E-3A2A-4EBD-A3D9-C476A4F5B5FDQ39136809-EE5A27E6-CAE5-491B-B625-51B936BFD4EEQ39315990-765D87F5-DD55-4193-8E2A-D00D21F1B39BQ39425755-FC1AEB0A-4486-49FA-9B09-BA35B46AC583Q40051077-49CE5008-1190-47E3-A231-D81538EAFE6EQ40055570-203333F9-1AC1-46CA-B78B-BB31DBE6FF1CQ40078335-92F22CCB-062F-4361-BCFC-9183336F084FQ40128225-71C81AFE-5C6C-4AD2-B808-B4A9AEFA3244Q40180038-312E0650-BCE5-4C9E-A3EB-6D08AF6C9504Q40335813-6CFC40A2-5E13-476E-94BE-D595CFE741DBQ40498729-3FCE7AB1-2B5D-4827-9C43-168FAEA2AD83Q40680454-BEA13C02-22FF-4FFE-BC6A-CF4AD3AACE6FQ41921732-72C9EC45-D5DF-4886-9F6C-1CB9B21CC785Q42318295-52C8D60E-04B0-4E0A-9735-E4169B3B61FBQ47552661-894DAEA3-A2D4-4536-B8A6-A4F819658758Q47578625-2279057E-3D64-4573-9E13-58052D66D1E4Q50326421-FE6D0FCF-3ADA-473C-83A7-99D2820EC0DAQ52764230-2C5234B9-74D5-4F4B-B04C-EAD5BA18E5F9Q58772479-226BB6FE-E561-47A6-9497-99DD72F191BE
P2860
Global strategies are required to cure and eliminate HBV infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Global strategies are required to cure and eliminate HBV infection.
@en
Global strategies are required to cure and eliminate HBV infection.
@nl
type
label
Global strategies are required to cure and eliminate HBV infection.
@en
Global strategies are required to cure and eliminate HBV infection.
@nl
prefLabel
Global strategies are required to cure and eliminate HBV infection.
@en
Global strategies are required to cure and eliminate HBV infection.
@nl
P2860
P50
P356
P1476
Global strategies are required to cure and eliminate HBV infection
@en
P2093
Stephen Locarnini
P2860
P2888
P304
P356
10.1038/NRGASTRO.2016.7
P407
P577
2016-02-24T00:00:00Z